RARRES3 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q9UL19 |
Other Accession | NP_004576.2 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 18179 Da |
Antigen Region | 43-71 aa |
Gene ID | 5920 |
---|---|
Other Names | Retinoic acid receptor responder protein 3, 311-, HRAS-like suppressor 4, HRSL4, RAR-responsive protein TIG3, Retinoid-inducible gene 1 protein, Tazarotene-induced gene 3 protein, RARRES3, RIG1, TIG3 |
Target/Specificity | This RARRES3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 43-71 amino acids from the Central region of human RARRES3. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | RARRES3 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | PLAAT4 (HGNC:9869) |
---|---|
Synonyms | RARRES3, RIG1, TIG3 |
Function | Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:19615464, PubMed:22605381, PubMed:22825852, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2), catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:19615464, PubMed:22605381, PubMed:22825852). For most substrates, PLA1 activity is much higher than PLA2 activity (PubMed:19615464). Shows O- acyltransferase activity, catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid (PubMed:19615464). Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N- acylphosphatidylethanolamine (NAPE), which serves as precursor for N- acylethanolamines (NAEs) (PubMed:19615464, PubMed:22605381, PubMed:22825852). Promotes keratinocyte differentiation via activation of TGM1 (PubMed:17762858). |
Cellular Location | Membrane; Single- pass membrane protein |
Tissue Location | Widely expressed. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. These effects are mediated by specific nuclear receptor proteins that are members of the steroid and thyroid hormone receptor superfamily of transcriptional regulators. RARRES1, RARRES2, and RARRES3 are genes whose expression is upregulated by the synthetic retinoid tazarotene. RARRES3 is thought act as a tumor suppressor or growth regulator.
References
Silva, L.K., et al. Eur. J. Hum. Genet. 18(11):1221-1227(2010)
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Uyama, T., et al. Biochim. Biophys. Acta 1791(12):1114-1124(2009)
Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
Higuchi, E., et al. Oncogene 22(30):4627-4635(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.